Mast Therapeutics Looks For Buyer

San Diego-based biopharmaceuticals developer Mast Therapeutics announced this morning that it is evaluating "strategic opportunities", and is considering a reverse merger, licensing of its assets, as well as continued clinical development of its lead compound. The company said it received "several written indications of interest" from private held companies in terms of a reverse merger. Mast Therapeutics is publicly traded on the NYSE at MSTX. The company has been investigating drugs for treating heart failure.